Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Farletuzumab - Morphotek

Drug Profile

Farletuzumab - Morphotek

Alternative Names: Anti-GP-3 humanised mAb; Anti-GP3 humanised monoclonal antibody; MORAb-003

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ludwig Institute for Cancer Research; Morphotek
  • Developer Eisai Co Ltd; Morphotek
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Folate receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (IV, Infusion)
  • 03 Oct 2016 Farletuzumab licensed to Eurofarma in Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top